President Donald Trump has nominated Heidi Overton, a White House aide, to lead the Food and Drug Administration (FDA), according to a senior administration official. This decision follows the departure of former commissioner Marty Makary earlier this year, which left the agency facing challenges in U.S. drug development. Overton currently serves as the deputy director of the White House Domestic Policy Council and was among several candidates considered for the position. Bloomberg was the first to report her nomination.
Overton recently participated in an event where an executive order was signed to revise the childhood vaccine schedule, which includes reducing the number of federally recommended vaccines and separating the MMR vaccine into three individual shots. She stated, "We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out."
Some analysts express concerns about Overton's lack of experience in leadership roles, with Chris Meekins, a Raymond James analyst and former Trump health official, suggesting that her confirmation could lead to setbacks in the agency's relationship with the pharmaceutical industry. Conversely, Brian Blase, president of the Paragon Health Institute, praised Overton as a "great choice," highlighting her character and dedication to improving American healthcare.
The nomination will require approval from the Senate, where Overton's recent involvement in vaccine policy may face scrutiny, particularly from outgoing Senate health committee chair Bill Cassidy, who has criticized the executive order.